Matches in SemOpenAlex for { <https://semopenalex.org/work/W4206631671> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4206631671 endingPage "92" @default.
- W4206631671 startingPage "92" @default.
- W4206631671 abstract "Introduction: Chemotherapy-induced nausea and vomiting (CINV) is a distressing side-effect of cancer chemotherapy which may lead to noncompliance with treatment or delay in treatment. Breakthrough nausea and vomiting is the current unmet need in the management in of CINV. Objectives: The present study was planned to determine the prevalence of breakthrough CINV in patients on highly emetogenic chemotherapy (HEC) and to evaluate the need for rescue medications in them. Materials and Methods: The present observational study was conducted on chemotherapy-naive patients, who were scheduled to receive HEC. The patients who received at least 2 cycles of HEC over a 1-year study period enrolled as a study sample. All patients were subjected to a questionnaire which consists of the demographic details, details of disease and prescribed chemotherapy, and probable risk factors for CINV. The severity of nausea vomiting was calculated using the Multinational Association of Supportive Care in Cancer antiemetic tool. The incidence of breakthrough nausea vomiting was assessed and accordingly the rescue medication was used. Results: A total of 100 patients received at least 2 cycles of HEC which consisted of breast carcinomas (n = 74), ovarian carcinoma (n = 13), lung carcinoma (n = 2), periampullary carcinoma (n = 3), sarcoma (n = 4), lymphoma (n = 3), and seminoma (n = 1). Anthracycline-cyclophosphamide combination for breast cancer was the most prescribed chemotherapy regimen. Forty-six patients developed breakthrough nausea/vomiting. Domperidone followed by olanzapine was the preferred rescue medications used. History of CINV in previous cycle and young age (<50 years) were the risk factors associated with breakthrough nausea vomiting in our study. Conclusion: Breakthrough nausea vomiting is a major challenge in patients receiving HEC regimen." @default.
- W4206631671 created "2022-01-25" @default.
- W4206631671 creator A5008006041 @default.
- W4206631671 creator A5019131496 @default.
- W4206631671 creator A5022520483 @default.
- W4206631671 creator A5037052711 @default.
- W4206631671 creator A5054285788 @default.
- W4206631671 creator A5055561758 @default.
- W4206631671 date "2021-01-01" @default.
- W4206631671 modified "2023-10-01" @default.
- W4206631671 title "Prevalence of breakthrough chemotherapy-induced nausea vomiting in patients on highly emetogenic chemotherapy: A Single-center observational study" @default.
- W4206631671 cites W1528154222 @default.
- W4206631671 cites W1966606652 @default.
- W4206631671 cites W1970880506 @default.
- W4206631671 cites W2007857130 @default.
- W4206631671 cites W2012005071 @default.
- W4206631671 cites W2030136010 @default.
- W4206631671 cites W2105467170 @default.
- W4206631671 cites W2132184189 @default.
- W4206631671 cites W2148594906 @default.
- W4206631671 cites W2164502847 @default.
- W4206631671 cites W2327612061 @default.
- W4206631671 cites W2488120510 @default.
- W4206631671 cites W2558713444 @default.
- W4206631671 cites W2604708549 @default.
- W4206631671 cites W2726372533 @default.
- W4206631671 cites W3034944798 @default.
- W4206631671 cites W4243894673 @default.
- W4206631671 doi "https://doi.org/10.4103/oji.oji_22_21" @default.
- W4206631671 hasPublicationYear "2021" @default.
- W4206631671 type Work @default.
- W4206631671 citedByCount "1" @default.
- W4206631671 countsByYear W42066316712023 @default.
- W4206631671 crossrefType "journal-article" @default.
- W4206631671 hasAuthorship W4206631671A5008006041 @default.
- W4206631671 hasAuthorship W4206631671A5019131496 @default.
- W4206631671 hasAuthorship W4206631671A5022520483 @default.
- W4206631671 hasAuthorship W4206631671A5037052711 @default.
- W4206631671 hasAuthorship W4206631671A5054285788 @default.
- W4206631671 hasAuthorship W4206631671A5055561758 @default.
- W4206631671 hasConcept C121608353 @default.
- W4206631671 hasConcept C126322002 @default.
- W4206631671 hasConcept C2776694085 @default.
- W4206631671 hasConcept C2779924295 @default.
- W4206631671 hasConcept C2780574406 @default.
- W4206631671 hasConcept C2780580376 @default.
- W4206631671 hasConcept C2780852908 @default.
- W4206631671 hasConcept C2780884295 @default.
- W4206631671 hasConcept C530470458 @default.
- W4206631671 hasConcept C71924100 @default.
- W4206631671 hasConceptScore W4206631671C121608353 @default.
- W4206631671 hasConceptScore W4206631671C126322002 @default.
- W4206631671 hasConceptScore W4206631671C2776694085 @default.
- W4206631671 hasConceptScore W4206631671C2779924295 @default.
- W4206631671 hasConceptScore W4206631671C2780574406 @default.
- W4206631671 hasConceptScore W4206631671C2780580376 @default.
- W4206631671 hasConceptScore W4206631671C2780852908 @default.
- W4206631671 hasConceptScore W4206631671C2780884295 @default.
- W4206631671 hasConceptScore W4206631671C530470458 @default.
- W4206631671 hasConceptScore W4206631671C71924100 @default.
- W4206631671 hasIssue "3" @default.
- W4206631671 hasLocation W42066316711 @default.
- W4206631671 hasOpenAccess W4206631671 @default.
- W4206631671 hasPrimaryLocation W42066316711 @default.
- W4206631671 hasRelatedWork W1480067006 @default.
- W4206631671 hasRelatedWork W2032692004 @default.
- W4206631671 hasRelatedWork W2037755310 @default.
- W4206631671 hasRelatedWork W2045947004 @default.
- W4206631671 hasRelatedWork W2074264434 @default.
- W4206631671 hasRelatedWork W2080135046 @default.
- W4206631671 hasRelatedWork W2240215470 @default.
- W4206631671 hasRelatedWork W2307524438 @default.
- W4206631671 hasRelatedWork W2438751362 @default.
- W4206631671 hasRelatedWork W3093970226 @default.
- W4206631671 hasVolume "5" @default.
- W4206631671 isParatext "false" @default.
- W4206631671 isRetracted "false" @default.
- W4206631671 workType "article" @default.